Navigation Links
Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase the Maximal Steady State Subcutaneous Bioavailability from 64% to 100% -

SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that final results of the Enhanze(TM) Technology clinical trial demonstrating improved absorption and bioavailability of a representative commercially-available large protein molecule therapeutic (LPMT) were presented at the 34th Annual Meeting of the Controlled Release Society in Long Beach, California. Enhanze Technology is Halozyme's enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20). The abstract describing this trial was rated by the Controlled Release Society as having notable high scientific quality and was designated for a podium presentation, which included a recently completed modeled population pharmacokinetic (PK) analysis used to estimate the effect of steady state co-administration of rHuPH20 with the LPMT.

This clinical trial, sponsored and funded solely by Halozyme, compared the PK, safety, and tolerability of an LPMT agent subcutaneously (SC) injected first without Enhanze Technology (rHuPH20) and then with rHuPH20 in 15 patients. The representative LPMT selected for this trial was HUMIRA(R) (adalimumab), based on the product being readily commercially available, well-recognized, labeled for SC route of administration, and for which a validated assay for PK profiling could be developed. The open-label cross-over study used escalating doses of rHuPH20 (ranging from 1,600 U to 12,800 U) and a fixed dose of HUMIRA (40 mg) injected every two weeks. Patients with rheumatoid arthritis on maintenance HUMIRA were crossed-over to a single SC injection of HUMIRA co-injected with rHuPH20, and the two injections were compared with regard to PK and s afety. HUMIRA is a registered trademark of Abbott Laboratories.

The data from this clinical trial support the study hypothesis that rHuPH20 increases the relative bioavailability of the SC injected HUMIRA:

    -- For the primary endpoint of area under the curve (AUC) for adalimumab

       plasma concentration, the AUC over the 14 days following administration

       was higher when the HUMIRA was co-injected with rHuPH20 compared to the

       HUMIRA injection without rHuPH20 for 100% (15/15) of the patients in

       the study.

    -- The modeled population PK analysis estimated a 59% maximal increase in

       the relative SC bioavailability of adalimumab at steady state if

       co-injected with rHuPH20; thus, the reported reference 64% SC absolute

       bioavailability HUMIRA injected alone was estimated to increase to 100%

       when co-injected with rHuPH20, achieving essentially complete


    -- The modeled PK analysis estimated that a high dose of rHuPH20 (at least

       6,400 U) was required to assure the maximal rHuPH20 effect.

    -- Injection of rHuPH20 with HUMIRA was well tolerated at all rHuPH20 dose

       levels, without dose-limiting toxicity, premature withdrawals, or

       serious adverse events.  Of the total of five adverse events reported

       in this study, two were assessed as having no association with either

       study drug (basal cell carcinoma and urinary tract infection).  The

       remaining three events consisted of mild injection site erythema

       (redness) that occurred on the day of the co-injection and resolved

       within one or two days.

As a spreading agent, hyaluronidase has traditionally been used to accelerate the delivery of drugs and fluids, including local anesthetics, other co-injected drugs, and contrast agents, and for subcutaneous fluid replacement. Although a large body of clinical experience supports the benefits and safety of using hyaluronidase as an adjuvant to increase the absorption and dispersion of co-injected small molecule drugs, to Halozyme's knowledge, this was the first clinical trial conducted to support the benefits and safety of rHuPH20 for use with large molecule agents, such as monoclonal antibodies and other large molecule biologics. Most therapeutic antibodies are 60% to 70% systemically bioavailable following SC injection, allowing room for improvement in absorption. Other therapeutic large molecule agents have even lower systemic bioavailability, and still other agents may not be developed for SC administration because of low systemic bioavailability through this route of administration. rHuPH20 is the first and only hyaluronidase from a recombinant human source that is FDA-approved, currently in a 150 U product configuration.

"The remarkable findings from this clinical trial, estimating that co-injection of rHuPH20 in high doses can boost the SC absolute bioavailability of an LPMT from 64% to essentially 100%, validates similar findings from animal models," said Richard C. Yocum, MD, Vice President of Clinical Development and Medical Affairs at Halozyme. "We have shown previously in two different animal species and with three different representative large molecules that rHuPH20 locally co-injected with the large molecule increases the bioavailability in a rHuPH20 dose-dependent fashion and to essentially complete absorption."

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition, the company has received FDA approval for two pr oducts: Cumulase(R) and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the applicability of rHuPH20 to large protein molecule therapeutics) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

    Halozyme Contact                  Investor Relations Contact

    David A. Ramsay                   Don Markley

    Chief Financial Officer           Lippert/Heilshorn & Associates

    (858) 794-8881                    (310) 691-7100


                                      Media Contacts

                                      Karen Sparks / Joleen Schultz


                                      (858) 455-5500, x275/x215



CONTACT: David A. Ramsay, Chief Financial Officer of HalozymeTherapeutics, Inc., +1-858-794-8881, ; or investorrelations, Don Markley of Lippert-Heilshorn & Associates, +1-310-691-7100,, for Halozyme Therapeutics, Inc.; or media, Karen Sparks,ext. 275, , or Joleen Schultz, ext. 215,, both of Mentus, +1-858-455-5500, for HalozymeTherapeutics, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:HALO)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
7. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... most successful and prominent nonprofit healthcare organizations in the country. They have overseen ... various organizations, and helped advance the healthcare industry as a whole through their ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
Breaking Medicine News(10 mins):